AnaptysBio Inc (GB:0HFQ)
LSE:0HFQ

AnaptysBio (0HFQ) Income Statement

0 Followers

AnaptysBio Income Statement

Last quarter (Q1 2023), AnaptysBio's total revenue was $1.37M, an increase of 41.65% from the same quarter last year. In Q1, AnaptysBio's net income was $-44.26M. See AnaptysBio’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 10.69M$ 10.29M$ 63.17M$ 75.00M$ 8.00M$ 5.00M
Cost of Revenue
------
Gross Profit
$ 8.18M$ 10.29M----
Operating Expense
$ 72.94M$ -125.44M$ 119.99M$ 98.88M$ 115.43M$ 71.72M
Operating Income
$ -127.81M$ -115.15M$ -56.81M$ -23.88M$ -107.43M$ -66.72M
Net Non Operating Interest Income Expense
$ -8.85M$ -13.56M$ -1.02M$ 3.96M$ 9.94M$ 5.03M
Other Income Expense
$ 18.00K$ -12.00K$ 37.00K$ -11.00K$ 1.00K$ -159.00K
Pretax Income
$ -136.65M$ -128.70M$ -57.80M$ -19.93M$ -97.49M$ -61.85M
Tax Provision
$ 24.00K$ 24.00K$ 0.00$ 0.00$ -152.00K$ -192.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -136.68M$ -128.72M$ -57.80M$ -19.93M$ -97.34M$ -61.66M
Basic EPS
$ -4.84$ -4.57$ -2.11$ -0.73$ -3.60$ -2.50
Diluted EPS
$ -4.84$ -4.57$ -2.11$ -0.73$ -3.60$ -2.50
Basic Average Shares
$ 112.61M$ 28.16M$ 27.43M$ 27.30M$ 27.06M$ 24.67M
Diluted Average Shares
$ 112.61M$ 28.16M$ 27.43M$ 27.30M$ 27.06M$ 24.67M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 72.94M$ -125.44M$ 119.99M$ 98.88M$ 115.43M$ 71.72M
Net Income From Continuing And Discontinued Operation
$ -136.68M$ -128.72M$ -57.80M$ -19.93M$ -97.34M$ -61.66M
Normalized Income
$ -66.06M-$ -57.80M$ -19.93M$ -97.34M$ -61.66M
Interest Expense
$ 12.00M-$ 1.45M$ 0.00$ 1.04M$ 1.65M
EBIT
$ -124.44M$ -115.14M$ -56.35M$ -19.93M$ -96.45M$ -60.20M
EBITDA
$ -124.27M$ -112.81M$ -54.26M$ -18.31M$ -95.93M$ -59.88M
Currency in USD

AnaptysBio Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis